5 / 34
No validated biomarkers available
•
VHL Status and antiangiogenic treatment
•
miRNA and response to Sunitinib
•
MET expression and PD-L1 expression were not found predictive of clinical activity for cabozantinib (METEOR Trial) or
nivolumab (CheckMate 025)
•
No patient selection has been made by FGFR, KIT or RET status for treatment with Lenvatinib